Table 1 Demographic characteristics, AD biomarkers, and ATN groups of the participants by diagnostic category
From: Glial activation and inflammation along the Alzheimer’s disease continuum
Variable | Groups | X2(p) | Dunn’s pair-wise comparisons | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
1. Healthy controls (n = 36) | 2. Aβ + SCD (n = 18) | 3. Aβ + MCI (n = 40) | 4. AD dementia (n = 27) | 1 vs 2 | 1 vs 3 | 1 vs 4 | 2 vs 3 | 2 vs 4 | 3 vs 4 | ||
Age | 61.1 (9.2) | 67.2 (6.6) | 66.6 (7.4) | 67.6 (5.2) | X2 = 14.4 (< .01) | n.s. | < .05 | < .05 | n.s. | n.s. | n.s. |
Female % | 19 (53%) | 8 (44%) | 23 (57%) | 13 (48%) | X2 = 1.6 (n.s.) | a | a | a | a | a | a |
MMSE | 29.4 (0.7) | 29.2 (0.8) | 27.9 (2.0) | 19.0 (5.8) | X2 = 83.7 (< .001) | n.s. | < .001 | < .001 | < .01 | < .001 | < .001 |
APOE-ɛ4 positivity (%) | 16 (44%) | 13 (72%) | 23 (57%) | 9 (33%) | X2 = 6.8 (n.s.) | a | a | a | a | a | a |
CSF Aβ42 | 1044 (185) | 530 (98) | 474 (112) | 473 (93) | b | b | b | b | b | b | |
CSF Total tau | 298 (97) | 487 (249) | 635 (290) | 961 (417) | X2 = 58.0 (< .001) | < .05 | < .001 | < .001 | n.s. | < .01 | < .05 |
CSF P-tau | 51 (13) | 74 (33) | 86 (40) | 89 (43) | X2 = 37.2 (< .001) | < .05 | < .001 | < .001 | n.s. | n.s. | n.s. |
A−T−N−, n (%) | 36 (100%) | 0 (0%) | 0 (0%) | 0 (0%) | b | b | b | b | b | b | |
A+T−N−, n (%) | 0 (0%) | 10 (55%) | 13 (33%) | 0 (0%) | b | b | b | b | b | b | |
A+T−N+, n (%) | 0 (0%) | 1 (5%) | 10 (25%) | 19 (70%) | b | b | b | b | b | b | |
A+T+N+, n (%) | 0 (0%) | 7 (40%) | 16 (40%) | 8 (30%) | b | b | b | b | b | b | |